Literature DB >> 2118936

Experimental study on multidisciplinary treatment of pancreatic cancer.

T Moriai1, T Takeba, I Makino.   

Abstract

We investigated the antitumor effects of intratumoral (IT) injection of mitomycin-C (MMC), 5-fluorouracil (5FU), adriamycin (ADR), cisplatin (CDDP), streptozotocin (STZ), and interleukin-2 (IL-2) on well-differentiated pancreatic ductal adenocarcinoma (WD PaCa), a solid tumor model in the Syrian golden hamster. The growth of established palpable WD PaCa was not suppressed by intraperitoneal (IP) injection of these anticancer agents, whereas IT injection of MMC (1.0 mg/kg or more), 5FU (12.5 mg/kg or more), and CDDP (2.5 mg/kg or more) caused significant and marked suppression. The growth of established palpable WD PaCa was transiently suppressed by 50 Gy of local irradiation. The antitumor effect of irradiation was not enhanced by it injection of MMC before irradiation, whereas it was significantly enhanced by it injection after irradiation. Intraperitoneal injection of IL-2 (5 or 10 micrograms/d, 18 d) slightly suppressed the growth of established palpable tumors, but it injection of IL-2 caused significant and marked suppression, eliminating the tumor in 10-20% of the animals. Findings in this animal model of pancreatic cancer suggest that it treatment of anticancer agents or IL-2 might become an effective therapy for advanced pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2118936     DOI: 10.1007/bf02924286

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN: 0169-4197


  16 in total

1.  Cancer of the pancreas (nonendocrine): a suggested morphologic classification.

Authors:  A L Cubilla; P J Fitzgerald
Journal:  Semin Oncol       Date:  1979-09       Impact factor: 4.929

2.  Results in the management of locally unresectable pancreatic carcinoma.

Authors:  M T Selch; R G Parker
Journal:  Am J Clin Oncol       Date:  1986-04       Impact factor: 2.339

3.  Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.

Authors:  E J Freireich; E A Gehan; D P Rall; L H Schmidt; H E Skipper
Journal:  Cancer Chemother Rep       Date:  1966-05

4.  Natural killer (NK) cells as a responder to interleukin 2 (IL 2). II. IL 2-induced interferon gamma production.

Authors:  K Handa; R Suzuki; H Matsui; Y Shimizu; K Kumagai
Journal:  J Immunol       Date:  1983-02       Impact factor: 5.422

5.  Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest Oncology Group study.

Authors:  R M Bukowski; S P Balcerzak; R M O'Bryan; J D Bonnet; T T Chen
Journal:  Cancer       Date:  1983-11-01       Impact factor: 6.860

6.  Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide.

Authors:  S Silagi; A E Schaefer
Journal:  J Biol Response Mod       Date:  1986-10

7.  Local and systemic effects during interleukin-2 therapy of mouse mammary tumors.

Authors:  J Vaage
Journal:  Cancer Res       Date:  1987-08-15       Impact factor: 12.701

8.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.

Authors:  S A Rosenberg; P Spiess; R Lafreniere
Journal:  Science       Date:  1986-09-19       Impact factor: 47.728

9.  Phase II trial of 5-fluorouracil, adriamycin, mitomycin C, and streptozotocin (FAM-S) in pancreatic carcinoma.

Authors:  R M Bukowski; L P Schacter; C W Groppe; J S Hewlett; J K Weick; R B Livingston
Journal:  Cancer       Date:  1982-07-15       Impact factor: 6.860

10.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

Authors:  S A Rosenberg; J J Mulé; P J Spiess; C M Reichert; S L Schwarz
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.